Press Release: Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with deepening improvements in post-swallow residue and total dysphagic symptom burden as compared to the 12-month follow-up timepoint
CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025, in line with prior financial guidance.
NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed on behalf of all former stockholders of Smartsheet Inc. (NYSE: SMAR) in connection with the January 2025 sale (the “Merger” or “Buyout”) of Smartsheet to affiliates of…
DUBAI, United Arab Emirates, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Mutuum Finance (MUTM) has provided a new update on its technical roadmap as development for its decentralized lending protocol continues. The team confirmed that security auditing has progressed as planned and that work on the first public version of the protocol is moving forward. Mutuum…
SACRAMENTO, CA, Jan. 10, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not medical advice. Always consult a qualified healthcare professional before making changes to your health routine. If you purchase through links in this article, a commission may be earned at no additional cost to you.
